115 related articles for article (PubMed ID: 22449053)
1. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice.
Sevko A; Kremer V; Falk C; Umansky L; Shurin MR; Shurin GV; Umansky V
J Immunotoxicol; 2012; 9(3):275-81. PubMed ID: 22449053
[TBL] [Abstract][Full Text] [Related]
2. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
[TBL] [Abstract][Full Text] [Related]
3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
4. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
5. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
6. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
8. Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice.
Tanaka K; Ishikawa S; Matsui Y; Kawanishi T; Tamesada M; Harashima N; Harada M
Cancer Immunol Immunother; 2012 Nov; 61(11):2143-52. PubMed ID: 22588648
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors.
Umansky V; Abschuetz O; Osen W; Ramacher M; Zhao F; Kato M; Schadendorf D
Cancer Res; 2008 Nov; 68(22):9451-8. PubMed ID: 19010920
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ
Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
12. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
Steitz J; Tormo D; Schweichel D; Tüting T
Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes.
De Palma R; Marigo I; Del Galdo F; De Santo C; Serafini P; Cingarlini S; Tüting T; Lenz J; Basso G; Milan G; Zanovello P; Bronte V
Cancer Res; 2004 Nov; 64(21):8068-76. PubMed ID: 15520218
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity.
Yan X; Zhang X; Wang Y; Li X; Wang S; Zhao B; Li Y; Ju Y; Chen L; Liu W; Meng S
Cancer Immunol Immunother; 2011 Dec; 60(12):1763-74. PubMed ID: 21789592
[TBL] [Abstract][Full Text] [Related]
15. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
16. CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.
Sfondrini L; Besusso D; Bronte V; Macino B; Rossini A; Colombo MP; Ménard S; Balsari A
Cancer Immunol Immunother; 2004 Aug; 53(8):697-704. PubMed ID: 15034674
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
18. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
19. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
20. Effect of Aerva lanata on cell-mediated immune responses and cytotoxic T-lymphocyte generation in normal and tumor-bearing mice.
Siveen KS; Kuttan G
J Immunotoxicol; 2012; 9(1):25-33. PubMed ID: 22129065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
